Healthcare Professionals

Aesculap Biologics, LLC pursues biologic and combination (device/biologic) products to meet the changing needs of the health care environment.

Aesculap Biologics, with its development partner TETEC, AG (based in Reutlingen, Germany), is focused on cartilage repair and regeneration using a collaborative approach with surgeons to uncover unmet medical needs across the world. Within the United States, Aesculap Biologics is currently conducting a Phase 3 trial of NOVOCART® 3D, evaluating efficacy and safety as compared to Microfracture in the repair of articular cartilage of the femoral condyle.

Future products that may come to the U.S. market for development include cartilage repair in the spine (NOVOCART DISC), hip, knee and ankle.